David Reisman

7.2k total citations · 2 hit papers
93 papers, 5.9k citations indexed

About

David Reisman is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, David Reisman has authored 93 papers receiving a total of 5.9k indexed citations (citations by other indexed papers that have themselves been cited), including 64 papers in Molecular Biology, 45 papers in Oncology and 24 papers in Pathology and Forensic Medicine. Recurrent topics in David Reisman's work include Chromatin Remodeling and Cancer (30 papers), Cancer-related Molecular Pathways (26 papers) and Cancer Mechanisms and Therapy (22 papers). David Reisman is often cited by papers focused on Chromatin Remodeling and Cancer (30 papers), Cancer-related Molecular Pathways (26 papers) and Cancer Mechanisms and Therapy (22 papers). David Reisman collaborates with scholars based in United States, Israel and Canada. David Reisman's co-authors include Bill Sugden, John Yates, Selina Glaros, Bernard E. Weissman, E. Aubrey Thompson, Varda Rotter, Weidong Wang, Bryan L. Betz, William K. Funkhouser and B Roy and has published in prestigious journals such as Nature, Proceedings of the National Academy of Sciences and Nucleic Acids Research.

In The Last Decade

David Reisman

92 papers receiving 5.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A cis-acting element from the Epstein-Barr viral genome that permits stable replication of recombinant plasmids in latently infected cells.

1984 579 citations David Reisman et al. profile →
A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components.

1985 391 citations David Reisman et al. profile →

Peers

Countries citing papers authored by David Reisman

Since Specialization

Citations

This map shows the geographic impact of David Reisman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Reisman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Reisman more than expected).

Fields of papers citing papers by David Reisman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Reisman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Reisman. The network helps show where David Reisman may publish in the future.

Co-authorship network of co-authors of David Reisman

This figure shows the co-authorship network connecting the top 25 collaborators of David Reisman. A scholar is included among the top collaborators of David Reisman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Reisman. David Reisman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	HER2 Overexpression Triggers an IL1α Proinflammatory Circuit to Drive Tumorigenesis and Promote Chemotherapy Resistance 2018 ·Cancer Research ·Shou Liu, Ji Shin Lee, Chunfa Jie, Min Ho Park, Yoichiro Iwakura, Yogin Patel, (unknown), David Reisman, Hexin Chen	68
2	Palliative treatment of patients with inoperable locally advanced, recurrent or metastatic head and neck squamous cell cancer, using a low-dose and personalized chemotherapeutic regimen 2017 ·Oncology Letters ·Rohit Bishnoi, (unknown), David Reisman	3
3	A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth 2016 ·Oncotarget ·Yogin Patel, Nirav Shah, Ji Shin Lee, Eleni Markoutsa, Chunfa Jie, Shou Liu, (unknown), David Reisman, Peisheng Xu, Hexin Chen	54
4	GP88 (progranulin): a novel tissue and circulating biomarker for non–small cell lung carcinoma 2014 ·Human Pathology ·Martin J. Edelman, Josephine Feliciano, Binbin Yue, P.A. Bejarano, Olga B. Ioffe, David Reisman, Douglas M. Hawkins, (unknown), David G. Hicks, Ginette Serrero	46
5	The bidirectional p53–Wrap53β promoter is controlled by common cis- and trans-regulatory elements 2014 ·Gene ·(unknown), David Reisman	5
6	Identifying targets for the restoration and reactivation of BRM 2013 ·Oncogene ·(unknown), (unknown), (unknown), (unknown), Li Lu, David Reisman	40
7	Elevated transcription of the p53 gene in early S-phase leads to a rapid DNA-damage response during S-phase of the cell cycle 2011 ·APOPTOSIS ·(unknown), (unknown), David Reisman	24
8	The chromatin remodelling factor BRG1 is a novel binding partner of the tumor suppressor p16INK4a 2009 ·Molecular Cancer ·Therese M. Becker, Sebastian Haferkamp, M K Dijkstra, Lyndee L. Scurr, (unknown), Eve Diefenbach, Richard A. Scolyer, David Reisman, Graham J. Mann, Richard Kefford, Helen Rizos	47
9	Targeted Knockout of BRG1 Potentiates Lung Cancer Development 2008 ·Cancer Research ·Selina Glaros, (unknown), Ariel Palanca, Daniel Metzger, David Reisman	69
10	C/EBPβ Participates in Regulating Transcription of the p53 Gene in Response to Mitogen Stimulation 2007 ·Journal of Biological Chemistry ·Kristy Boggs, David Reisman	30
11	Transcriptional Regulation of the p53 Tumor Suppressor Gene: A Potential Target for Cancer Therapeutics? 2007 ·PubMed ·David Reisman, Kristy Boggs	8
12	Localization of a mutant p53 response element on the Tissue Inhibitor of Metalloproteinase-3 promoter: Mutant p53 activities are distinct from wild-type 2005 ·Cancer Letters ·Shana Thomas, David Reisman	4
13	Increased p53 transcription prior to DNA synthesis is regulated through a novel regulatory element within the p53 promoter 2005 ·Oncogene ·Kristy Boggs, David Reisman	25
14	The Expression of the SWI/SNF ATPase Subunits BRG1 and BRM in Normal Human Tissues 2005 ·Applied immunohistochemistry & molecular morphology ·David Reisman, (unknown), Thomas W. Bouldin, Bernard E. Weissman, William K. Funkhouser	65
15	Compensation of BRG-1 Function by Brm 2002 ·Journal of Biological Chemistry ·Matthew W. Strobeck, David Reisman, Ranjaka W. Gunawardena, Bryan L. Betz, Steven P. Angus, Karen E. Knudsen, Timothy F. Kowalik, Bernard E. Weissman, Erik S. Knudsen	100
16	Concomitant down-regulation of BRM and BRG1 in human tumor cell lines: differential effects on RB-mediated growth arrest vs CD44 expression 2002 ·Oncogene ·David Reisman, Matthew W. Strobeck, Bryan L. Betz, (unknown), William K. Funkhouser, (unknown), Moshé Yaniv, Larry S. Sherman, Erik S. Knudsen, Bernard E. Weissman	132
17	Transcriptional regulation of the p53 tumor suppressor gene 1998 ·Seminars in Cancer Biology ·David Reisman, William Loging	57
18	A Novel Transcript Encoded within the 10-kb First Intron of the Human p53 Tumor Suppressor Gene (D17S2179E) Is Induced during Differentiation of Myeloid Leukemia Cells 1996 ·Genomics ·David Reisman, Éva Bálint, William Loging, Varda Rotter, Einat Almon	20
19	The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene 1993 ·Nucleic Acids Research ·David Reisman, Varda Rotter	102
20	The size and topology of single-stranded DNA from bean golden mosaic virus 1979 ·Virology ·David Reisman, Robert P. Ricciardi, Robert M. Goodman	13

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact